Higher levels of CXCR2 and TGF-β were observed in patients with breast cancer and other types of cancer where they were always correlated with worse clinical outcomes (Ivanović et al., 2006; Li et al., 2011; Gao et al., 2015; Schinke et al., 2015). This evidence concerns the gene CXCR2 and breast carcinoma.